GSE138824
Vascular smooth muscle selective deletion of Srf
Previous efforts to conditionally delete the Srf transcription factor in smooth muscle lineages were met with early demise of the mouse due to a gastrointestinal (GI) obstruction phenotype. We have developed a new, more VSMC selective Cre recombinase mouse (Itga8-CreERT2), that circumvents the GI phenotype thus affording the opportunity to evaluate, in an unambiguous manner, VSMC phenotypes where Srf is reduced.  The mice live for at least 6 months post-tamoxifen and here we report the first RNA-seq experiments in mouse aortic SMC where Srf is reduced. Overall design: Mice homozygous or heterozygous for a floxed Srf allele and hemizygous for the Itga8-CreERT2 driver were treated with 5 daily doses of 33mg/kg Tamoxifen (i.p.).  Aortae from the experimental homozygous cKO (n=3) or the control heterozygous cKO (n=3) were harvested 10 days following the last tamoxifen injection.  Only 2 homozygous cKO replicates are reported here due to an outlier effect (or error in sampling) in one of the experimental samples.  Thus, the data herein reflect only 2 homoygous cKOs and 3 heterozygous cKO controls.